Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC/MM Fusion Vaccine + Elranatamab in Relapsed/Refractory Multiple Myeloma
NCT06799026Phase 1Recruiting
- Sponsor
- David Avigan
- Start
- Jan 2025
- Primary completion
- Sep 2028
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dendritic cell-myeloma fusion vaccine in multiple myeloma (MM), sponsored by David Avigan. Primary endpoints: Administration of DC/MM Vaccine at 1 year, Grade 3-4 Non-hematologic Toxicity Rate at 1 year and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
dendritic cell-myeloma fusion vaccine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06799026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06799026.